Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 134 participants.

Also called NCT01002339

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
Armando Torres Ramírez (from the registry)
Registry
  • NCT NCT01002339
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01002339. Randomized; no masking; primary purpose prevention. Start 2010-02 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2016-08-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
Acronym
01-DMPT
Condition
Diabetes Mellitus, Adult-Onset
Intervention (Drug)
Tacrolimus with rapid steroid withdrawal
Intervention (Drug)
Tacrolimus with steroids minimization
Intervention (Drug)
CsA with steroid minimization
Lead sponsor
Armando Torres Ramírez (class: other)

Record details

Record id
cardio:ct-nct01002339
Content hash
5139524d20084412dee4417d50bc4b95f0ac3f0a4b628ae3b56652c41ecbbd88